Insider Selling: Edwards Lifesciences Co. (NYSE:EW) VP Sells 857 Shares of Stock

Edwards Lifesciences Co. (NYSE:EW) VP Daniel J. Lippis sold 857 shares of Edwards Lifesciences stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $85.60, for a total transaction of $73,359.20. Following the sale, the vice president now directly owns 23,890 shares of the company’s stock, valued at approximately $2,044,984. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Edwards Lifesciences Price Performance

EW traded up $2.33 during trading on Thursday, reaching $87.42. The stock had a trading volume of 3,421,899 shares, compared to its average volume of 3,709,712. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. The business has a 50-day moving average of $90.03 and a 200-day moving average of $79.73. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12. The stock has a market cap of $52.68 billion, a PE ratio of 37.68, a PEG ratio of 3.59 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.02. The business had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. As a group, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.77 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on EW. Barclays boosted their price target on shares of Edwards Lifesciences from $100.00 to $101.00 and gave the company an “overweight” rating in a report on Tuesday. Piper Sandler boosted their price objective on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company a “neutral” rating in a research report on Friday, April 26th. Royal Bank of Canada boosted their price objective on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research report on Monday, April 15th. OTR Global raised shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. Finally, Stifel Nicolaus boosted their price objective on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the company a “hold” rating in a research report on Friday, April 26th. One analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $93.27.

Institutional Investors Weigh In On Edwards Lifesciences

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in Edwards Lifesciences by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 52,363,400 shares of the medical research company’s stock worth $3,992,709,000 after buying an additional 729,984 shares during the period. Bank of New York Mellon Corp raised its position in shares of Edwards Lifesciences by 9.5% in the 1st quarter. Bank of New York Mellon Corp now owns 18,973,304 shares of the medical research company’s stock worth $1,813,089,000 after acquiring an additional 1,644,869 shares in the last quarter. Brown Advisory Inc. lifted its stake in shares of Edwards Lifesciences by 20.1% in the 4th quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock valued at $1,386,333,000 after purchasing an additional 3,048,274 shares during the period. Wellington Management Group LLP boosted its position in shares of Edwards Lifesciences by 2.4% during the fourth quarter. Wellington Management Group LLP now owns 16,827,510 shares of the medical research company’s stock valued at $1,283,098,000 after purchasing an additional 393,109 shares in the last quarter. Finally, Norges Bank purchased a new stake in Edwards Lifesciences in the fourth quarter worth $648,540,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.